N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease.
The polymerase chain reaction (PCR) and allele specific oligonucleotide (ASO) hybridization have been used to investigate the incidence of N-ras mutation in acute myeloid leukemia (AML). The prognostic significance of these mutations and their value as markers of minimal residual disease have also been assessed. Mutated N-ras alleles were detected in 9 of 69 AML patients (13%). No significant difference in survival or remission duration was found between those patients with an N-ras mutation and those without. Four patients with N-ras mutations at presentation were followed through disease progression. The results showed no consistent pattern of association between the presence of an N-ras mutation and disease state.
Casey
G
G
Department of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia.
Rudzki
Z
Z
Roberts
M
M
Hutchins
C
C
Juttner
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D011905:Genes, ras / Q000235:genetics*; D005819:Genetic Markers; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies
D005819:Genetic Markers